A Two-part Phase 1 Randomized, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3862995B Following Single Ascending Doses in Healthy Participants and Repeat Doses in Participants With Chronic Obstructive Pulmonary Disease
Latest Information Update: 30 Apr 2025
At a glance
- Drugs GSK-3862995B (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 25 Apr 2025 Planned End Date changed from 27 Apr 2026 to 26 Jun 2026.
- 25 Apr 2025 Planned primary completion date changed from 27 Apr 2026 to 26 Jun 2026.
- 12 Aug 2024 Planned End Date changed from 13 Mar 2026 to 27 Apr 2026.